Key points of basic theories and clinical practice in rAd-p53 (Gendicine™) gene therapy for solid malignant tumors

Abstract

Introduction: Wild-type p53 gene is an essential cancer suppressor gene which plays an important role in carcinogenesis and malignant progressions. The p53 gene family participates in almost all the key procedures of cancer biology, such as programmed cell death, angiogenesis, metabolism and epithelial-mesenchymal transition. The mutation or functional defects of the p53 gene family are detected in most of the solid malignant tumors, and the restoration of the p53 gene by adenovirus-mediated gene therapy becomes a promising treatment for cancer patients now.

Areas covered: In the present review, the potential therapeutic effects of recombinant adenovirus p53 rAd-p53 (Gendicine™) were reviewed to explore the biological mechanism underlying the adenovirus-mediated p53 gene therapy. Then, the key points of the drug administration were discussed, including the routes of administration, dosage calculation and treatment cycles, based on findings of the preclinical and clinical trials in order to establish a standard treatment for the p53 gene therapy.

Expert opinion: As an important part of the combined therapy for the cancer patients, the adenovirus-mediated p53 gene therapy was blossomed to be a promising treatment strategy. A new evaluation criteria and guideline for the gene therapy is urgently needed for the further clinical practice.

Keywords:

• basic theory
• clinical practice
• gene therapy
• recombinant adenovirus p53
• solid cancer

Acknowledgment

Y Li and B Li have equally contributed to this work.

Declaration of interest

The study was supported by the National Natural Science Foundation of China (Grant Nos. 81001209 and 81172578) and the Foundation for Innovative Research Groups of the National Natural Science Foundation of China (Grant No. 81321002). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Notes